All News

PD-L1, KIM-1 Levels May Predict Kidney Cancer Response to Opdivo, Yervoy

November 20th 2024, 10:00pm

Article

PD-L1 expression was found to predict better outcomes with Opdivo and Yervoy in patients with ccRCC, while high KIM-1 levels were linked to worse outcomes.

Donor Lymphocyte Infusion May Improve Survival in R/R MDS

November 20th 2024, 8:00pm

Article

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

It's OK Not to Have Full Holiday Spirit During Cancer

November 20th 2024, 6:00pm

Article

During the holiday season, overwhelming feelings are OK to have, whether you are a patient with cancer or a caregiver.

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

November 20th 2024, 4:00pm

Article

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

What Patients with Breast Cancer Need to Know About Lymphedema Risk

November 20th 2024, 2:00pm

Article

CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.

Newer Therapies for Acute Lymphoblastic Leukemia May Reduce Side Effects

November 19th 2024, 10:00pm

Article

New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.

Venclexta Regimen Beneficial for Patients with AML and MDS

November 19th 2024, 8:00pm

Article

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

My Top 10 List for Living With Cancer

November 19th 2024, 6:00pm

Article

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Why Clinical Trials Don’t Have to Be Patients’ ‘Last Line of Defense’

November 19th 2024, 4:00pm

Article

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients with cancer to enroll.

Columvi Shows High Response Rates and Safety in R/R Mantle Cell Lymphoma

November 19th 2024, 2:00pm

Article

Treatment with Columvi showed a manageable safety profile in heavily pre-treated patients with relapsed or refractory mantle cell lymphoma.